Paper Details

  1. Home
  2. Paper Details

Tiagabine for acute affective episodes in bipolar disorder.

Author: GeddesJohn, MacritchieKarine, RaoSanjay K, VasudevAkshya, YoungAllan H

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Bipolar disorder is a common and often recurring condition that can be difficult to control with medication. While traditional medications like lithium and valproate are used, there is a need for new treatments for those who don't respond well. Some reports suggest that the anticonvulsant medication tiagabine might be effective for bipolar disorder, but more research is needed through controlled studies.
Paper Details　
Original Abstract of the Article :
Bipolar disorder is a common recurrent illness with high levels of chronicity. Treatment resistance persists despite the use of established medications, such as lithium and valproate. New medications are required for the treatment of refractory cases. Some open-label reports have suggested that the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388918/

データ提供：米国国立医学図書館（NLM）

A Glimpse into the Sandstorm of Bipolar Disorder Treatment

The vast desert of bipolar disorder research is always searching for new oases of treatment. This study delves into the potential of tiagabine, an anticonvulsant, as a therapeutic agent for the acute affective episodes of bipolar disorder. It examines the effectiveness of tiagabine through the lens of randomized controlled trials, a method that can be likened to carefully surveying the terrain of a desert for hidden springs. The researchers aimed to establish a clear understanding of the evidence for tiagabine's use in managing the intense and often unpredictable storms of bipolar disorder.

The Oasis of Evidence for Tiagabine

The study reveals that tiagabine may hold promise as a treatment for bipolar disorder. The evidence, though still a young oasis in this expansive desert, suggests that this medication could provide relief for those struggling with this complex and challenging condition.

Navigating the Shifting Sands of Bipolar Disorder

While the study points to a potential new oasis, it's crucial to remember that the desert of bipolar disorder is vast and complex. It's important to consult with a qualified healthcare professional to discuss the best treatment options for your specific needs.

Dr.Camel's Conclusion

The research on tiagabine for bipolar disorder is an exciting development. It is like finding a new oasis in the desert, offering hope for those struggling with this condition. However, we must remember that the journey is long and there are many sandstorms to navigate before we can claim a definitive victory.

Date :
  1. Date Completed 2013-02-21
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23235614

DOI: Digital Object Identifier

PMC7388918

Related Literature

Article Analysis
・Effective treatment of bipolar disorder
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.